<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01228110</url>
  </required_header>
  <id_info>
    <org_study_id>06111972</org_study_id>
    <nct_id>NCT01228110</nct_id>
  </id_info>
  <brief_title>Corticosteroids in Community Acquired Pneumonea</brief_title>
  <official_title>Corticosteroids and ICU Course of Community Acquired Pneumonia in Egyptian Settings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low dose hydrocortisone IV in patients with CAP fastens recovery of pneumonia and prevents&#xD;
      the development of sepsis related complications with a significant reduction in duration of&#xD;
      mechanical ventilation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion Criteria Minor criteria includes&#xD;
&#xD;
        -  respiratory rate &gt; 30 bpm at admission;&#xD;
&#xD;
        -  ratio of PaO2 to fraction of inspired oxygen (PaO2:FIO2 ) &lt; 250;&#xD;
&#xD;
        -  chest radiograph showing bilateral involvement or multilobar involvement;&#xD;
&#xD;
        -  systolic blood pressure &lt; 90 mm Hg; or&#xD;
&#xD;
        -  diastolic blood pressure &lt; 60 mm Hg. Major criteria includes&#xD;
&#xD;
        -  Requirement of MV;&#xD;
&#xD;
        -  Increase in the size of opacities on chest radiograph of 50% or more at 48 hours;&#xD;
&#xD;
        -  Requirement of vasopressors for more than 4 hours; or&#xD;
&#xD;
        -  Serum creatinine 2 mg/dl or more.&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
        -  Children;&#xD;
&#xD;
        -  Nosocomial pneumonia;&#xD;
&#xD;
        -  Hospitalisation within the previous 14 days;&#xD;
&#xD;
        -  Severe immunosuppression (chronic use of systemic steroids);&#xD;
&#xD;
        -  Non-steroid immunosuppressive treatment or HIV);&#xD;
&#xD;
        -  Chronic chest disease; , tuberculosis, aspiration or obstructive pneumonia;&#xD;
&#xD;
        -  Congestive heart failure (cerebrovascular stroke);&#xD;
&#xD;
        -  Chronic renal or hepatic disease;&#xD;
&#xD;
        -  Acute burn injury;&#xD;
&#xD;
        -  Malignancy;&#xD;
&#xD;
        -  Pregnancy; and&#xD;
&#xD;
        -  Major gastrointestinal bleed within 3 months of the current hospitalization&#xD;
&#xD;
      Study Outcome The end-points of the study were improvement in PaO2:FIO2 (PaO2:FIO2 &gt; 300 or&#xD;
      ≥100 increase from study entry) and sepsis related organ failure assessment, (SOFA) score by&#xD;
      day 8 and the development of delayed septic shock.&#xD;
&#xD;
      The adopted SOFA score (up to 6 points) was proposed by Vincent et al., [21]. The number of&#xD;
      MV-free days was defined as the number of days after ventilation was discontinued up to study&#xD;
      day 8. Shock was defined as requirement of vasopressors. ARDS was defined by consensus&#xD;
      criteria.&#xD;
&#xD;
      All the patients were subjected to&#xD;
&#xD;
        1. Routine laboratory screen, including CBC, RBS, serum urea and creatinine, liver enzymes,&#xD;
           serum billirubin and coagulation profiles;&#xD;
&#xD;
        2. Chest X ray on at least on admission and at day 8;&#xD;
&#xD;
        3. ABG at least once daily to detect PaO2:FIO2;&#xD;
&#xD;
        4. CRP daily from day 1 to 8 and&#xD;
&#xD;
        5. Evaluation of SOFA score daily&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PaO2:FIO2</measure>
    <description>improvement in PaO2:FIO2 (PaO2:FIO2 &gt; 300 or ≥100 increase from study entry) and sepsis related organ failure assessment, (SOFA) score by day 8 and the development of delayed septic shock.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Community Acquired Pneumonia</condition>
  <arm_group>
    <arm_group_label>Corticosteroid group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group was entitled to receive hydrocortisone 200 mg loading bolus followed by an intravenous infusion (300 mg in 500 ml 0.9% saline) at a rate of 12.5 mg/hour for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group was meant to receive placebo (sterile normal saline in a volume equal to the study drug).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortison</intervention_name>
    <arm_group_label>Corticosteroid group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Solution</intervention_name>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Minor criteria included&#xD;
&#xD;
          -  respiratory rate &gt; 30 bpm at admission;&#xD;
&#xD;
          -  ratio of PaO2 to fraction of inspired oxygen (PaO2:FIO2 ) &lt; 250;&#xD;
&#xD;
          -  chest radiograph showing bilateral involvement or multilobar involvement;&#xD;
&#xD;
          -  systolic blood pressure &lt; 90 mm Hg; or&#xD;
&#xD;
          -  diastolic blood pressure &lt; 60 mm Hg. Major criteria included&#xD;
&#xD;
          -  Requirement of MV;&#xD;
&#xD;
          -  Increase in the size of opacities on chest radiograph of 50% or more at 48 hours;&#xD;
&#xD;
          -  Requirement of vasopressors for more than 4 hours; or&#xD;
&#xD;
          -  Serum creatinine 2 mg/dl or more. 10&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children;&#xD;
&#xD;
          -  Nosocomial pneumonia;&#xD;
&#xD;
          -  Hospitalisation within the previous 14 days;&#xD;
&#xD;
          -  Severe immunosuppression (chronic use of systemic steroids);&#xD;
&#xD;
          -  Non-steroid immunosuppressive treatment or HIV);&#xD;
&#xD;
          -  Chronic chest disease; , tuberculosis, aspiration or obstructive pneumonia;&#xD;
&#xD;
          -  Congestive heart failure (cerebrovascular stroke);&#xD;
&#xD;
          -  Chronic renal or hepatic disease;&#xD;
&#xD;
          -  Acute burn injury;&#xD;
&#xD;
          -  Malignancy;&#xD;
&#xD;
          -  Pregnancy; and&#xD;
&#xD;
          -  Major gastrointestinal bleed within 3 months of the current hospitalization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>October 25, 2010</study_first_submitted>
  <study_first_submitted_qc>October 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2010</study_first_posted>
  <last_update_submitted>October 25, 2010</last_update_submitted>
  <last_update_submitted_qc>October 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>Emad El-Din Omar</name_title>
    <organization>Cairo University</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

